We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

CEO John Leonard said the company will focus its resources largely on two late-stage programs amid a “challenging market environment.” Intellia Therapeutics Inc. is shedding employees and ...

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027 ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

The inducement grant consisted of time-based restricted stock units ("RSUs”) for 21,863 shares of Intellia's common stock, ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep the engine running until a potential commercial launch in 2027.

https://www.tipranks.com/news/the-fly/hookipa-pharma-announces-enrollment-completion-of-phase-1b-hb-500-trial BMO Capital lowered the firm’s price target on ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Intellia Therapeutics will stop work on one of its principal drug research programs and lay off more than ...